Your browser doesn't support javascript.
loading
Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases.
Lu, Yaoyao; Happi Mbakam, Cedric; Song, Bo; Bendavid, Eli; Tremblay, Jacques-P.
Afiliação
  • Lu Y; CHU de Québec Research Center, Laval University, Quebec City, QC, Canada.
  • Happi Mbakam C; Department of Molecular Medicine, Laval University, Quebec City, QC, Canada.
  • Song B; CHU de Québec Research Center, Laval University, Quebec City, QC, Canada.
  • Bendavid E; Department of Molecular Medicine, Laval University, Quebec City, QC, Canada.
  • Tremblay JP; CHU de Québec Research Center, Laval University, Quebec City, QC, Canada.
Front Genome Ed ; 4: 892769, 2022.
Article em En | MEDLINE | ID: mdl-35958050
ABSTRACT
Advancements in genome editing make possible to exploit the functions of enzymes for efficient DNA modifications with tremendous potential to treat human genetic diseases. Several nuclease genome editing strategies including Meganucleases (MNs), Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) have been developed for the correction of genetic mutations. CRISPR-Cas has further been engineered to create nickase genome editing tools including Base editors and Prime editors with much precision and efficacy. In this review, we summarized recent improvements in nuclease and nickase genome editing approaches for the treatment of genetic diseases. We also highlighted some limitations for the translation of these approaches into clinical applications.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article